M. K. Cho, Y. P. Jang, Y. C. Kim and S. G. Kim, “Arctigenin, a Phenylpropanoid Dibenzylbutyrolactone Lignan, Inhibits MAP Kinases and AP-1 Activation via Potent MKK Inhibition: The Role in TNF-α Inhibition,” International Immunopharmacology, Vol. 4, No. 10-11, 2004, pp. 1419-1429. doi:10.1016/j.intimp.2004.06.011

has been cited by the following article:

• TITLE: Induction of Apoptosis and Acetylation of Histone H3 and H4 by Arctigenin in the Human Melanoma Cell Line SK-MEL-28

  AUTHORS: Jin Boo Jeong, Se Chul Hong, Jin Suk Koo, Hyung Jin Jeong

  KEYWORDS: Arctigenin, Apoptosis, Histone Acetylation, Caspases, Melanoma

  JOURNAL NAME: Food and Nutrition Sciences, Vol.2 No.2, March 31, 2011

  ABSTRACT: Cutaneous melanoma is one of the most aggressive forms of skin cancer. Arctigenin, one of the major bioactive compo-nents of Arctii Fructus, has been reported to exhibit antioxidant, antitumor and anti-inflammatory activities. In the pre-sent study, we investigated the effect of arctigenin on induction of apoptosis in highly metastatic SK-MEL-28 human melanoma cells. Arctigenin inhibited growth of SK-MEL-28 cells in a dose-dependent manner. Treatment of SK-MEL-28cells with arctigenin caused cleavage of caspases 3, 7 and 9, and poly (ADP-ribose) polymerase in a dose-dependent manner. Furthermore, acetylation of histone H3 and H4 in the SK-MEL-28 cells was dramatically increased by arctigenin treatment. Collectively, these findings indicate that arctigenin-induces apoptosis of SK-MEL-28 melanoma cells via activation of caspases and histone acetylation.